Forbion is a leading European venture capital firm at the forefront of biotech innovation with over €5 billion in assets under management. With a proven track record in advancing the future of medicine, Forbion recently launched a new strategy to leverage biotechnology to tackle global environmental challenges, embodying its dedication to impact-driven investment alongside returns.
Forbion closed Ventures VII and Growth III in H2 2024 with both strategies investing in life sciences companies focused on drug discovery and development. Both funds exceeded their original target sizes and reached €1.2 billion ($1.3 billion) and €890 million ($980 million) respectively. The firm will likely return to market with Ventures VIII and Growth IV in 2026.
